Clinical Impact of Microbiome Characteristics in Treatment-Naïve Extranodal NK/T-Cell Lymphoma PatientsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Stool samples from 40 newly diagnosed, treatment-naive patients with extranodal natural killer/T-cell lymphoma (ENKTL) were analyzed to characterize the gut microbiome and its clinical associations.
How was it studied?
Whole genome shotgun sequencing was performed on stool samples and compared against healthy controls, with additional comparison to diffuse large B-cell lymphoma (DLBCL) patients.
What did they find?
ENKTL patients had reduced alpha diversity versus healthy controls, and Enterobacteriaceae abundance drove the beta diversity difference between groups. Enterobacteriaceae correlated with C-reactive protein, disease stage, PINK and PINK-E prognostic scores, early relapse, and shorter progression-free survival. ENKTL showed a distinct dominance of Escherichia, unlike the Enterobacter and Citrobacter prevalence seen in DLBCL, and Escherichia abundance correlated with tissue PD-L1 levels.
Why it matters
These findings suggest the ENKTL gut microbiome, particularly Enterobacteriaceae and Escherichia, may serve as a biomarker of disease severity and outcome and could play a role in lymphomagenesis, warranting further study.